IRM three-lens brief
Evidence-based stock research on IRM. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Outperforming SPY by 17.1pp over 30 days. · Trading at 99% of its 52-week range — near the top of the band.
- Trading at 99% of its 52-week range — near the top of the band.
- RSI at 75 — technically overbought.
- Outperforming SPY by 17.1pp over 30 days.
- P/E of 139 — priced for high growth; little margin of safety.
- Negative free cash flow last quarterly (-$499.46M).
IRM closed at $127.87 (+0.53%) as of 2026-05-04. Market cap: $38.04B. P/E (trailing) 139.0. Positives: outperforming SPY by 17.1pp over 30 days.. Concerns: trading at 99% of its 52-week range — near the top of the band.; rSI at 75 — technically overbought.. Last quarter: Revenue $1.94B, net income $143.66M, free cash flow -$499.46M.
Why three lenses on IRM, not one.
A single reasoning model has blind spots it doesn’t know about. We examine IRMacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/IRM" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath IRM brief"></iframe>